CCHFV Neutralizing Antibodies from Convalescent Donors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for developing vaccines and therapeutic antibodies against Crimean-Congo Hemorrhagic Fever Virus (CCHFV) are inadequate, with no approved vaccines and limited effective treatments, highlighting the need for novel strategies to induce protective immune responses.
Innovation Solution
Discovery and characterization of a panel of CCHFV-specific monoclonal antibodies from convalescent donors, which recognize epitopes on the Gc subunit of the virus, demonstrating potent neutralizing activity and potential for therapeutic and prophylactic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ribavirin is used to treat CCHFV infection, then some beneficial effects are observed in early phase, but mortality rate shows no significant change and there are safety concerns for pregnant women
Solution Approach 1:
The patent employs monoclonal antibodies as disposable therapeutic agents that can be administered directly to patients. These antibodies provide immediate neutralizing activity against CCHFV without the prolonged safety concerns associated with ribavirin, particularly for pregnant women. The antibodies act as single-use therapeutic interventions that neutralize the virus rapidly.
Solution Approach 2:
The monoclonal antibodies serve as intermediary molecules that bridge the gap between the immune system and the virus. Rather than using ribavirin which directly inhibits viral RNA synthesis but carries safety risks, the antibodies act as natural immune mediators that specifically bind and neutralize CCHFV, providing a safer therapeutic alternative.
2Productivity
If neutralizing monoclonal antibodies are isolated from immunized mice, then antibodies can be obtained, but the specificities and functional properties of human antibodies remain unknown
Solution Approach 1:
The patent creates a copy of the human immune response by isolating monoclonal antibodies directly from convalescent human donors. This approach copies the exact human antibody characteristics, specificities, and functional properties that are lost when using mouse models. The human-derived antibodies preserve all native human immune system features.
Solution Approach 2:
Instead of the conventional approach of immunizing animals and hoping to obtain human-relevant antibodies, the patent inverts the process by directly harvesting antibodies from human donors who have naturally recovered from CCHFV. This reversal ensures that the antibodies inherently possess human-specific characteristics without requiring translation from animal models.
3Reliability
If vaccines are developed against CCHFV, then protective immune responses can be induced, but no approved vaccines exist despite decades of research
Solution Approach 1:
The patent takes preliminary action by isolating and characterizing neutralizing monoclonal antibodies from convalescent donors before vaccine development is complete. These antibodies serve as ready-made protective agents that can be deployed immediately, bypassing the lengthy vaccine development process while providing the same protective immune function.
Solution Approach 2:
The monoclonal antibodies serve as intermediary protective agents that fulfill the role vaccines are intended to provide, but without requiring the long development timeline. These antibodies mediate protective immunity directly, acting as a bridge between natural infection recovery and formal vaccine approval.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide promising therapeutic candidates for reducing the severity and duration of CCHFV infections, offering a framework for rational vaccine design and potential use in combination with other agents for enhanced protective efficacy.
Implementation Method 1
Discovery and characterization of a panel of CCHFV-specific monoclonal antibodies from convalescent donors, which recognize epitopes on the Gc subunit of the virus
Data Source
AI summary
Anti-CCHFV antibodies with neutralizing potency and protective efficacy against CCHFV are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.